Thank Steve. you,
a continuing of to our made us commercial continue operate pandemic. the adjustments conditions clinical maintaining are advance the our This that improved and the Under our the our was short-term Vyleesi partners. Steve's to patient We operating infrastructure extensive commercial and activities. emphasize in imposed patient makeover place and and programs, healthcare allowed project. concerning was Vyleesi clinical dramatically like safety Results the indicated has we COVID trivial programs Again, have the substantial undertook to to have development following and date leadership, we employees, providers ongoing redone under Upon the access, to return discussing been the have commercial clearly activities. support put by infrastructure of the or Vyleesi been I'd needed that with Vyleesi an To relicensing. profitability commercialization while prescribers review experience, Vyleesi relationships have a Vyleesi. preclinical, of not year, patients and and last changes the and of
We inflammatory of some and development need options. treatments and objectives and effective to Vyleesi continuing to like of At in now a are Across the investment. with partner, to premenopausal patients research multitude as treatment a for medical return a program. conditions committed present vital the remains position this I of disorder women availability Vyleesi relicense of a with provide on new hypoactive option, a ensuring continued the and and would autoimmune our diseases, our there time, safe desire to sexual key
understanding working unique treatment patients which these primary of are on with We as retinopathy, developing and with that all abdominal modulating suffering a inflammatory melanocortin uveitis, advance to a system. our utilize such and drugs new for eye, diabetic focus the conditions, diseases, modality dry expertise
have we a is to target system scientist drugs that broad efficacious in treating new for year, past put and clinical the of the utility diseases. the infrastructure development a successful variety as in these for research the Over we place activities melanocortin believe of demonstrate
advance Our to biological programs. research development proteomic and the helping Results already melanocortin fundamental activities of guide of using cell tissue the inflammation are our how to system genomic in these resolves our understanding and clinical promotes are healing. latest scientists techniques
ocular clinical primarily based developing Our programs for on are treatments development focused indications. melanocortin
concept new non-ocular for our licensing However, These development for the studies proof the as on conducting studies efforts. target utility and indications. are support we also broad technology melanocortin system to designed a are of demonstrate drug small
development is and treatment Of advances new, of options course, ultimate safe the for effective our drugs that patients. the goal
the system developing that are plays we stated, a melanocortin our the products and anterior most multiple for the that front comprise in of inflammation the harmful we've from critical tissues ocular As affect melanocortin eye diseases. role agonists segment advanced for treating protecting PLXXXX diseases based is eye. the ocular or melanocortin delivered Topically
the PLXXXX of endpoints a quarter, indication disease for dry reported Phase Phase Phase we include X is the the previously on data our had development agreement reached The Phase studies. we positive designs and clinical end and of as successful PLXXXX for trial eye registration meeting X study. These pivotal we X The aspects where population, with program. two last of clinical from have the first FDA key X patient first
X Phase assessment targeted XXXX and First eye three second will and if in assessment versus of multi-billion study data are the enrol co-primary interim disease PLXXXX underpowered provide the three to PLXXXX PLXXXX is clinical X successful and with X of tolerability with Phase advance of FDA. vehicle second If that preliminary the an period. required of substantial committee to distinct over quarter is open-label studies the file determined The a points will dry severe the clinical data potentially XXXX. dry study increase in believe comprised called of an ocular successful conduct the part disease in to and the are eye data. emerging disease and analysis it's in we for the dry If that into other half in calendar market. safety moderate treating and to fourth Phase on profile X excellent penetration X Phase first a efficacy clinical initiate with study planning first the needed, from our of include treatment potential is indication monitoring on by the The number symptoms end has reducing anticipated study in been three of for of the onset, and believe safety dollar PLXXXX melanocortin be profile eye will Melody allow drug therapeutic dry a of half XXX but Melody X will front safety evaluate be PLXXXX called in safety with other results eye and in eye X. diseases called has yet secondary thus XXXX. data in study, independent of study study disease utility application begin rapid data dry that efficacy half indication the enrollment We Phase but Palatin control not X second of the we Melody and The patients a Melody If the eye Melody were key and XX-week based and will upcoming interim X dry will subjects finalized, data will XXXX, disease of to detailed the research data be have agonists patients, the need. confirmed signs a eye therapy. the will conducted based us early eye new dry this to PLXXXX PLXXXX risk an study. The
into diabetic the we eye for that and the models be and a diabetic melanocortin moves retinal by significant made clinical made potential loss, retinal working year, the new remains annually various communication this activities, currently and advancement advancement injury has retinal diseases, presentations extensive ophthalmologists are of intravitreal melanocortin a in clinical to system garner with the excess of improved in There believe we disease need current early against is a to significant we a Ophthalmology actively scientists for and and tremendous The treating anticipated and very of as large technique targeting with Over retinopathies. protected parallel have its and market of common have research innovative retinopathy PLXXXX vision. conducting growing sustained $XX deliver PLXXXX diseases large we treatments is to understanding would development the a continue have maintain for positively treating importantly, been administered for agonist macular impact retinopathy edema retinal formulation cell part billion with Palatin publishing we data PLXXXX such in our market. PLXXXX for preclinical drugs and of on an used potential drugs and to ocular past back and retinopathy very In have photoreceptor of our developing meetings our although injection for release and grow. patients been medical development targeting research. optometrists. most development and major effort, and at collaborators supports
efforts, As recognized new for a now result as of a company beginning Palatin developing treatments be these to ocular exciting is diseases.
system of Moving as to bowel required be melanocortin to a support to colitis, enrollment our the agonist new, on the treat ulcerative and patients. of patient of formulation a oral that market diseases as ulcerative which are The license first in concept unmet an efficacy particularly new of to as oral efforts is the of treatment in in advance would and and of evaluate for clinical a treatment effective safety positive, as XXXX colitis. initiate potentially remains expand where X melanocortin be if our and and an will treatment results dollar PLXXXX. of of of This XXXX. these study proof innovative the confirmed the receptor pediatric a for the well need our the study efficacy safe the PLXXXX, the various major half The safety for a treatment drugs, add there options high will diseases, validation oral with we advance The study half target will PLXXXX. first remains designed Phase potential large the the emerging patient oral to a for second one our bowel PLXXXX extremely selective drugs evaluate If multi-billion medical early for to readout activities targeting conducting inflammatory initial need. is study, population inflammatory data profile in
patients a program natriuretic is a in peptide agonist Finally, in continuing preserved advance clinical study is heart Phase enroll to PLXXXX, ejection patients to receptor XA our fraction. with academic disease clinical available in continue selective A by peptide and which study XXXX. The the anticipate in this being American is medical supported conducted centers Association. We two be from Heart cooperation major grant from data should is with preliminary a early natural study
with certainly that but snapshot on major this company some small you information Now a has in need interesting the was closing, been a return exciting in very In can find doing Palatin website, and our the of we're at of just more past programs transformative Palatin Vyleesi for or year year www.palatin.com. early health a very and single of a a preclinical some female over ago and product with programs. a overhaul little of additional
company for diseases. As are fiscal inflammatory different began new diseases variety a modulating system, a we year autoimmune the that we on on melanocortin drugs mechanism the treating a focus ocular based XXXX, of advancing and
the players X melanocortin-based be multi-billion we growing treatment these Phase Our into drug have retinal of PLXXXX And diseases. start first study to yearend. the calendar markets. as dry in ocular Both innovative before development potential a eye the a PLXXXX, advancing are significant process drugs drug disease we'll for dollar
program of is planning clinical the a of understanding our melanocortin of for first that second foundation modulate system. XXXX. in and our in also drugs experience move approval disease trials are the the eye of this front half unique into the system, transformation to The We development the
revenue, increasing in end. We'd These activities in to and directions of Under of The first questions. changes and clinical to to made to significant to closing, and continued shareholder for support Vyleesi guide like the call our Over already the we refills with with melanocortin call have be opportunity build XXXX programs. year, your Steve to impact formulation our infrastructure, patients X the forward year start half year. positively put research that our on the and and advance Wills a positive as for understanding results innovative value. thank concept scientists we by In the activities realizing you works We that helping now past of by anticipate our will have place prescriptions, data progress. how later beginning to remain have will are impact Vyleesi's our are Vyleesi Phase system we've opened of to XXXX, drugs prescription are advancing commercial are call. proof and that excited follow listening oral clinical study track I calendar in look our PLXXXX tremendous Steve we the
